Activase (alteplase)

Activase (alteplase) is filed as Tissue Plasminogen Activator (tPA). The sections below restate public label fields stored for this profile.

Class
Tissue Plasminogen Activator (tPA)
Generic name
alteplase
Route
Intravenous
Dosage forms
Increases the risk of bleeding. Avoid intramuscular injections. Monitor for bleeding. If serious bleeding occurs, discontinue Activase. ( 5.1 ) Monitor patients during and for several hours after infusion for hypersensitivity. If signs of hypersensitivity develop, discontinue Activase. ( 5.2 ) Consider the risk of reembolization from the lysis of underlying deep venous thrombi in patients with pulmonary embolism. ( 5.3 ) Cholesterol embolism has been reported rarely in patients treated with thrombolytic agents. ( 5.4 )
Manufacturer
Genentech, Inc.

Approved uses

Acute ischemic stroke Acute myocardial infarction Acute massive pulmonary embolism Restoration of function of central venous access devices

How it works

Binds to fibrin in a thrombus and converts entrapped plasminogen to plasmin, initiating local fibrinolysis with limited systemic proteolysis.

Warnings and precautions

Risk of serious and potentially fatal hemorrhage including intracranial hemorrhage. Strict time windows for stroke treatment (within 3–4.5 hours). Cholesterol embolism reported.

Contraindications

Active internal bleeding. History of recent stroke, intracranial surgery, or serious head trauma. Intracranial neoplasm, AVM, or aneurysm. Known bleeding diathesis. Severe uncontrolled hypertension.

Common side effects

Bleeding (any site) (Very common); Intracranial hemorrhage (~6% in stroke); Nausea/vomiting (Common); Hypotension (Common); Fever (Common); Angioedema/orolingual edema (1–5%)

Adverse reactions

ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in Section PRECAUTIONS of the label: Bleeding Hypersensitivity In the clinical trials, the most serious adverse events reported after treatment were sepsis (see PRECAUTIONS, Infections ), gastrointestinal bleeding, and venous thrombosis. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Trials 1 and 2 The data described for Trials 1 and 2 reflect exposure to Cathflo Activase in 1122 patients, of whom 880 received a single dose and 242 received two sequential doses of Cathflo Activase. In the Cathflo Activase Trials 1 and 2, only limited, focused types of serious adverse events were recorded, including death, major hemorrhage, intracranial hemorrhage, pulmonary or arterial emboli, and other serious adverse events not thought to be attributed to underlying disease or concurrent illness. Major hemorrhage was defined as severe blood loss ( > 5 mL/kg), blood loss requiring transfusion, or blood loss causing hypotension. Non‑serious adverse events and serious events thought to be due to underlying disease or concurrent illness were not recorded. Patients were observed for serious adverse events until catheter function was deemed to be restored or for a maximum of 4 or 6 hours depending on study. For most patients the observation period was 30 minutes to 2 hours. Spontaneously reported deaths and serious adverse events that were not thought to be related to the patient's underlying disease were also recorded during the 30 days following treatment. Four catheter-related sepsis events occurred from 15 minutes to 1 day after treatment with Alteplase, and a fifth sepsis event occurred on Day 3 after Alteplase treatment. All 5 patients had positive catheter or peripheral blood cultures within 24 hours after symptom onset. Three patients had a major hemorrhage from a gastrointestinal source from 2 to 3 days after Alteplase treatment. One case of injection site hemorrhage was observed at 4 hours after treatment in a patient with pre-existing thrombocytopenia. These events may have been related to underlying disease and treatments for malignancy, but a contribution to occurrence of the events from Alteplase cannot be ruled out. There were no reports of intracranial hemorrhage. Three cases of subclavian and upper extremity deep venous thrombosis were reported 3 to 7 days after treatment. These events may have been related to underlying disease or to the long-term presence of an indwelling catheter, but a contribution to occurrence of the events from Alteplase treatment cannot be ruled out. There were no reports of pulmonary emboli. There were no gender-related differences observed in the rates of adverse reactions. Adverse reactions profiles were similar across all age subgroups. Trial 3 In Trial 3 all serious adverse events were recorded with a specific interest in intracranial hemorrhage, major hemorrhage, thrombosis, embolic events, sepsis and catheter related complications. Major hemorrhage was defined as severe blood loss ( > 5 mL/kg), blood loss requiring transfusion, or blood loss causing hypotension. Non-serious adverse events were not recorded. Patients were observed until catheter function was deemed to be restored or for a maximum of 4 hours after the first dose. Additionally, serious adverse events were elicited from patients at 48 hours (up to 96 hours) following completion of treatment. No pediatric patients in Trial 3 experienced an intracranial hemorrhage, major hemorrhage, thrombosis, or an embolic event. Three cases of sepsis occurred 2 to 44 hours after treatment with Cathflo Activase. All of these patients had evidence of infection prior to administration of Cathflo Activase. An additional patient developed fever and lethargy within one day of Cathflo Activase administration, which required outpatient intravenous antibiotics. In one subject, the lumen of the catheter, placed 2 years previously, ruptured with infusion of the study drug. There were no gender-related differences observed in the rates of adverse reactions. Adverse reactions profiles were similar across all age groups.

Dosage and administration

Acute stroke: 0.9 mg/kg IV (max 90 mg): 10% as bolus, remainder over 60 min. Must be given within 3–4.5 hours of symptom onset. STEMI: 15 mg bolus, then 0.75 mg/kg over 30 min (max 50 mg), then 0.5 mg/kg over 60 min (max 35 mg). PE: 100 mg IV over 2 hours.

Drug interactions

Anticoagulants (heparin, warfarin) and antiplatelet agents increase bleeding risk. Avoid concurrent administration with other thrombolytics. ACE inhibitors may increase risk of angioedema.

Common questions

What is Activase approved to treat?

According to its FDA label, Activase (alteplase) is approved for: Acute ischemic stroke. Acute myocardial infarction. Acute massive pulmonary embolism For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Activase?

Activase (alteplase) belongs to the Tissue Plasminogen Activator (tPA) class of medications.

What form does Activase come in?

The FDA label lists Activase (alteplase) as: Increases the risk of bleeding. Avoid intramuscular injections. Monitor for bleeding. If serious bleeding occurs, discontinue Activase. ( 5.1 ) Monitor patients during and for several hours after infusion for hypersensitivity. If signs of hypersensitivity develop, discontinue Activase. ( 5.2 ) Consider the risk of reembolization from the lysis of underlying deep venous thrombi in patients with pulmonary embolism. ( 5.3 ) Cholesterol embolism has been reported rarely in patients treated with thrombolytic agents. ( 5.4 ); intravenous route. Available strengths and packaging vary by manufacturer.

Does Activase have a Boxed Warning?

Our ingest of the FDA label for Activase (alteplase) does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Activase cost?

Public CMS NADAC pricing for Activase (alteplase) is in the range Institutional: $6,000–$9,500 per 100 mg vial. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Activase currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Activase (alteplase) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Activase approved by the FDA?

The FDA record lists the approval date for Activase (alteplase) as 1987-11-13.

Who makes Activase?

The FDA label lists Genentech, Inc. as a labeler/manufacturer of Activase (alteplase). Multiple firms may market generics of the same molecule.

How should Activase be stored?

The FDA label states: "Activase is supplied as a sterile, lyophilized powder in 50 mg single-dose vials containing vacuum and in 100 mg single-dose vials without vacuum. Each 50 mg Activase vial (29 million IU) is packaged with diluent for rec…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…